Podcast:WOTY-How the Award has Changed the Face of the Industry.

Article

WOTY-How the Award has changed the face of the industry.

HBA’s CEO Laurie Cooke teams up with HBA President Ceci Zak, Vice President of general therapeutics for sanofi-aventis, to share how the Woman of the Year Award has changed the face of industry. PLUS: Ceci recounts how HBA has allowed her to “dream a dream”—one that she didn’t even know she had.

Listen to more Women of the Year podcast Series>>>
Recent Videos
Developing Non-Addictive Pain Medication
Related Content
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients

FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients

Don Tracy, Associate Editor
March 6th 2025
Article

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more than 35 years.

Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Heather Hunt

Healthcare’s Visual Future: Shaping Trust Through Design

Heather Hunt
March 6th 2025
Article

The six key design trends of 2025 redefine how healthcare brands can inspire trust and build lasting connections with their audiences.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

HEOR: From Proving Product Value to Proving Its Own Worth

HEOR: From Proving Product Value to Proving Its Own Worth

Yamini Misra;Denise Garner;Sarah Bandy, PhD;Sissi Pham
March 6th 2025
Article

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Jazz Pharmaceuticals Acquires Chimerix for $935 million

Jazz Pharmaceuticals Acquires Chimerix for $935 million

Don Tracy, Associate Editor
March 5th 2025
Article

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma.